To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
REUTERS/Kim Kyung-Hoon Astellas Pharma’s logo is pictured at its headquarters in Tokyo, Japan, December 3, 2019.
Jiji Press
12:08 JST, May 1, 2023
Tokyo (Jiji Press)—Japanese drugmaker Astellas Pharma Inc. said Monday that it has agreed to buy U.S. biopharmaceutical startup Iveric Bio Inc. for $5.9 billion in its largest corporate acquisition.
Astellas aims to complete the acquisition of Iveric, which develops ophthalmologic drugs, in July-September following U.S. antitrust and other regulatory screenings.
Astellas will take out bank loans and issue commercial paper to finance the acquisition.
Iveric, listed on the U.S. Nasdaq market, has applied for U.S. Food and Drug Administration approval for an age-related macular degeneration drug that is expected to help maintain or restore vision. The screening is expected to finish in August.
